The endophytic fungus Trametes hirsuta as a novel alternative source of podophyllotoxin and related aryl tetralin lignans

The aryl tetralin lignans are synthesized by Podophyllum sps. and are in great demand worldwide due to their use in synthesis of topoisomerase inhibitors. However, the sustained production of these aryl tetralin lignans requires large-scale harvesting from the natural environments, which has resulte...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of biotechnology 2006-04, Vol.122 (4), p.494-510
Hauptverfasser: Puri, Satish Chandra, Nazir, Asiya, Chawla, Raman, Arora, Rajesh, Riyaz-ul-Hasan, S., Amna, Touseef, Ahmed, Bilal, Verma, Vijeshwar, Singh, Shikha, Sagar, Ravinder, Sharma, Ashok, Kumar, Raj, Sharma, Rakesh Kumar, Qazi, Ghulam Nabi
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:The aryl tetralin lignans are synthesized by Podophyllum sps. and are in great demand worldwide due to their use in synthesis of topoisomerase inhibitors. However, the sustained production of these aryl tetralin lignans requires large-scale harvesting from the natural environments, which has resulted in the plant-endangered status. In view of the difficulties in their total chemical synthesis, cultivation and failure of metabolic engineering approaches, there is a need to search for alternative sources of production of aryl tetralin lignans. We unequivocally established the methodology for isolation, identification, and characterization of a novel fungal endophyte ( Trametes hirsuta) that produces aryl tetralin lignans consistently as shown by HPLC, LC–MS, LC/MS–MS and 1H NMR. The lignans produced by the microorganism are biologically active, and exhibit potent antioxidant, anticancer and radioprotective properties. This strategy promises to improve the production of these therapeutically important compounds at lower costs.
ISSN:0168-1656
1873-4863
DOI:10.1016/j.jbiotec.2005.10.015